New Releases from NCBI BookshelfDurvalumab (endometrial cancer, pMMR): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A24-86 [Internet].​Durvalumab (endometrial cancer, pMMR): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A24-86 [Internet].